… Although prospective comparative studies of these agents have been reported, sample size
limitations and heterogeneity among study participants mean that further research is needed …

… Background: The mechanism of action of bevacizumab and erlotinib is quite different in the
treatment of advanced non-small cell lung cancer (NSCLC). This study sought to compare …

… This study aimed to investigate the efficacy and safety of erlotinib plus … In this study, we
compared patient groups treated with erlotinib plus bevacizumab with those treated with erlotinib …

… afatinib versus erlotinib one-to-one, followed by one-to-two matching for gefitinib versus
erlotinib. … The balances between afatinib, erlotinib, and gefitinib were tested using standardized …

… Additional networks were created for the sensitivity analyses (erlotinib and gefitinib as separate
nodes with erlotinib defined as the reference treatment). Networks for subgroup analyses …

… In our study, we found that β-elemene plus erlotinib had a synergistic effect on the
proliferation and apoptosis of NCI-H1975 cells. β-elemene exerted potent reversal effects on TKI-…

… the difficulty posed by erlotinib resistance. Delivery systems … bioavailability and solubility
of erlotinib, thereby potentially … the precise administration of erlotinib to particular malignant …

… Patients were randomised to receive chemotherapy(Gemcitabine/docetaxel/paclitaxel/vinorelbine)
or TKI (erlotinib or gefitinib). Patients were evaluated at every visit for clinical benefit …

… studied that have really shown their lead over traditional formulations. This article summarizes
the novel erlotinib … Novel formulations of erlotinib will offer positive outcomes in cancer …

… for the treatments evaluated in this study [16]. Based on … to-head randomized comparative
studies, several systematic … erlotinib (34%); thus, the assumption was made that erlotinib and …